University of St Andrews spin out Pneumagen said that it has raised £2.5 million for clinical development of its Neumifil intranasal carbohydrate binding module (mCBM) for the prevention and treatment of respiratory viruses, including flu, RSV, and COVID-19. The company says that it previously raised £4 million investment for development of Neumifil, which is … [Read more...] about Pneumagen raises £2.5 million for clinical development of Neumifil nasal spray against flu, RSV, and COVID-19
Business
UC Davis spin out InVixa to develop inhaled statins for the treatment of COVID-19
A new spin out from the University of California, Davis called InVixa announced that it has acquired the rights to UC Davis intellectual property related to delivery of statins to the lung for the treatment of viral respiratory infections, including COVID-19. InVixa said that it expects to select a lead candidate following pre-clinical studies early this year and … [Read more...] about UC Davis spin out InVixa to develop inhaled statins for the treatment of COVID-19
Odyssey acquired intranasal therapy for the treatment of mild traumatic brain injury from Prevacus
Odyssey Group International said that it has signed a definitive agreement with Prevacus to acquire PRV-002, an intranasal therapy for the treatment of mild traumatic brain injury. As part of the deal, Prevacus CEO Jake Vanlandingham will join Odyssey. In 2017, Prevacus announced that it planned to initiate a Phase 1 trial of PRV-002; however, Prevacus has been … [Read more...] about Odyssey acquired intranasal therapy for the treatment of mild traumatic brain injury from Prevacus
AuraVax Therapeutics licences intranasal vaccine adjuvant technology from Massachusetts General Hospital
Intranasal vaccine developer AuraVax Therapeutics said that the company has licensed liposomal STING agonist technology from Massachusetts General Hospital (MGH) for use as an adjuvant in vaccines against COVID-19 and other respiratory diseases. The technology was developed by MGH researcher Mei X. Wu. AuraVax co-founder Navin Varadarajan commented, "We are … [Read more...] about AuraVax Therapeutics licences intranasal vaccine adjuvant technology from Massachusetts General Hospital
Acorda sells Inbrija manufacturing operations to Catalent
Catalent will pay Acorda Therapeutics $80 million cash for Acorda's manufacturing operations in Chelsea, MA, USA where the company makes Inbrija dry powder levodopa. According to Catalent, the 90,000 sq ft CGMP facility "will act as a global center of excellence within the Catalent network for spray-dried dispersion and dry powder encapsulation and … [Read more...] about Acorda sells Inbrija manufacturing operations to Catalent
Arcturus Therapeutics to develop inhaled CFTR mRNA therapy for CF
California-based Arcturus Therapeutics announced that it will develop its ARCT-032 aerosolized CFTR mRNA formulation for the treatment of cystic fibrosis. According to Arcturus, preclinical studies of ARCT-032, which is based on the company's LUNAR (lipid-enabled and unlocked nucleomonomer agent modified RNA) technology, have demonstrated that the inhaled therapy has … [Read more...] about Arcturus Therapeutics to develop inhaled CFTR mRNA therapy for CF
United Therapeutics to acquire priority review voucher for use with Tyvaso DPI NDA
United Therapeutics announced that it has agreed to pay $105 million for a rare pediatric disease priority review voucher that the company plans to use to get an 8-month FDA review of an NDA for its Tyvaso treprostinil DPI instead of the standard 12-month review. Submission of the NDA for the treatment of pulmonary arterial hypertension and pulmonary hypertension … [Read more...] about United Therapeutics to acquire priority review voucher for use with Tyvaso DPI NDA
Menarini acquires rights to market Ryaltris nasal spray in 33 European countries
Menarini will pay Glenmark an undisclosed amount up front plus milestone payments for exclusive rights to market Ryaltris olopatadine/mometasone furoate nasal spray in 33 European countries, Ryaltris developer Glenmark has announced. Glenmark will be continue to be responsible for European development and regulatory approval of the nasal spray for the treatment of … [Read more...] about Menarini acquires rights to market Ryaltris nasal spray in 33 European countries
Tonix to develop intranasal oxytocin for the treatment of insulin resistance and obesity
Several months after acquiring the rights to TNX-1900 oxytocin nasal spray for the treatment of migraine headaches from Trigemina, Tonix Pharmaceuticals announced that it has acquired an exclusive license to technology from the University of Geneva for the use of oxytocin to treat insulin resistance and related conditions such as obesity. The company has not yet … [Read more...] about Tonix to develop intranasal oxytocin for the treatment of insulin resistance and obesity
Hikma gets FDA approval for, and launches, generic version of Advair Diskus
Hikma Pharmaceuticals announced that the FDA has approved 100 mcg/50 mcg and 250 mcg/50 mcg doses of the company's fluticasone propionate / salmeterol DPI (VR315), a generic version of Advair Diskus and that the company has launched the inhaler in the US. The FDA had issued a minor CRL in response to the ANDA in September 2020. A previous CRL had been issued in May … [Read more...] about Hikma gets FDA approval for, and launches, generic version of Advair Diskus